The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Month: November 2023

FDA cracks down on illegal probiotic product usage for hospitalised preterm infants
Biotics and Supplements

FDA cracks down on illegal probiotic product usage for hospitalised preterm infants

NOV 30, 2023
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
Infectious Disease & AMR

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

NOV 29, 2023
Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
Finance

Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings

NOV 29, 2023
Morinaga Milk’s Probiotic Receives Approval of Individual Recognized Registration in South Korea
Biotics and Supplements

Morinaga Milk’s Probiotic Receives Approval of Individual Recognized Registration in South Korea

NOV 28, 2023
Boehringer Ingelheim acquires bacterial cancer therapy specialist T3 Pharma
Finance

Boehringer Ingelheim acquires bacterial cancer therapy specialist T3 Pharma

NOV 22, 2023
Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy
Clinical & Manufacturing

Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy

NOV 15, 2023
Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche
Finance

Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche

NOV 11, 2023
Mammalian cells may consume bacteria-killing viruses to promote cellular health
Pharma & Human Health

Mammalian cells may consume bacteria-killing viruses to promote cellular health

NOV 9, 2023
Canada approves gut-brain axis health claims for Chr. Hansen probiotic strain
Biotics and Supplements

Canada approves gut-brain axis health claims for Chr. Hansen probiotic strain

NOV 8, 2023
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
Clinical & Manufacturing

MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT

NOV 7, 2023
Seres Therapeutics announces strategic restructuring and third quarter financial results including VOWST™ net sales
Finance

Seres Therapeutics announces strategic restructuring and third quarter financial results including VOWST™ net sales

NOV 6, 2023